CRT (Cardiac resynchronisation therapy) devices to remain outside functional indication, FDA insists
This article was originally published in Clinica
Cardiac resynchronisation therapy (CRT) devices cannot take advantage of the novel functional indication - and associated reduced regulatory costs - enjoyed by some implantable cardioverter defibrillators (ICDs), the US FDA says in a new guidance document.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.